Citations

Clear

9383 citation(s) found for "Thomas, PS".

Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis
Sabik, Joseph F. , Rao, Vivek , Dagenais, François, Moront, Michael G., Patel, Himanshu J. , Oh, Jae K. , Fukuhara, Shinichi , Labrousse, Louis , Günzinger, Ralf, Wu, Tianhua, Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martin, Günzinger, Ralf, Lange, Rudiger, Chu, Michael , Reardon, Michael J , Patel, Himanshu J , Labrousse, Louis , Ito, Saki , Chu, Michael W A , Reardon, Michael J. , Baig, Kamran M. , Ito, Saki , Klautz, Robert J.M. , Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martín , Günzinger, Ralf, Lange, Rudiger

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 18, 2024 | Volume: 67 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezae414 | PMID 39565905 Get It

Abstract OBJECTIVES Safety, efficacy and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis. METHODS Patients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally. The primary end-point of this analysis was freedom from surgical explant or percutaneous valve-in-valve reintervention due to structural valve deterioration (SVD) at 7 years of follow-up, determined using Kaplan–Meier (KM) analysis. We also evaluated a composite end-point of SVD and/or severe haemodynamic dysfunction requiring reintervention. Survival, valve-related safety events and haemodynamic performance were assessed. Deaths and safety events were adjudicated by an independent clinical events committee. RESULTS A total of 1132 patients underwent surgical AVR. Mean age was 70 years; 854 patients (75%) were men. The mean STS risk of mortality was 2.0 ± 1.4%, and 659 patients (58%) had a New York Heart Association classification of I/II. One or more concomitant procedures were performed in 577 patients (51%). At 7 years, the Kaplan–Meier rate of freedom from SVD/severe haemodynamic dysfunction requiring reintervention was 1.2% (0.5–2.5%) with no cases adjudicated as SVD. The survival rate was 82.6% (79.5–85.0%). The KM event rate was 5.7% (4.3–7.7%) for reintervention, 6.3% (4.9–8.3%) for endocarditis and 0.4% (0.1–1.1%) for valve thrombosis. Mean aortic gradient, dimensionless velocity index and effective orifice area were 13.8 ± 5.9 mmHg, 0.42 ± 0.09 and 1.99 ± 0.53 cm2, respectively. CONCLUSIONS This analysis demonstrated excellent durability of the Avalus valve with good clinical outcomes and stable haemodynamic performance through 7 years of follow-up.
Implementation of pharmacogenomics: Experience at Ochsner Health
Oliver, Catherine B, Naik, Dhara, Kirkikis, Mark, Ghaffari, Mary , Oyen, Lance J., Thomas, Karen

Mayo Clinic

American Journal of Health-System Pharmacy | November 16, 2024 | Volume: 82 | Issue: 6 | Pages: 341-349

10.1093/ajhp/zxae295 | PMID 39549284 Get It

Abstract Purpose Pharmacogenomics is the study of how individual responses to medication are influenced by genetics. As medication experts, pharmacists are uniquely suited to practicing this application of precision medicine. Fundamental operational aspects of developing a pharmacy clinical pharmacogenomics practice are described, and the specific experience of a multisite health system in developing a pharmacogenomics service is discussed. Summary Considerations for the development of a clinical pharmacy–driven pharmacogenomics service include understanding testing selection, targeting the appropriate patient population, exploration of reimbursement, design of the practice, and education of the pharmacogenomics workforce. Testing can be preemptive or reactive, can occur in house or as a send-out service, and can be panel based or specific to a single gene. Pharmacogenomics is applicable to many medicine specialties, making deployment of services to strategic groups essential. Reimbursement for pharmacogenomics is variable and may pose a barrier to implementation. The demand for pharmacogenomics education for pharmacy students and as a formal postgraduate career path is growing. Pharmacogenomics service planning and implementation details for a multisite health system are described. Conclusion The practice of pharmacogenomics presents a remarkable opportunity for clinical pharmacists and health systems to improve patient care outcomes and experiences.
Two‐Stage Recruitment Design to Reduce Magnetic Resonance Imaging Screening Cost for a Theoretical Clinical Trial of White Matter Hyperintensity Progression
Egle, Marco , Johri, Mohini, Power, Melinda C. , Deal, Jennifer A. , Jack, Clifford R. , Sullivan, Kevin , Mosley, Thomas H. , Mosley, Thomas H. , Sullivan, Kevin J , Gottesman, Rebecca F , Jack, Clifford R , Deal, Jennifer A , Egle, Marco , Johri, Mohini, Gottesman, Rebecca F.

Mayo Clinic

Journal of the American Heart Association | November 16, 2024 | Volume: 13 | Issue: 22 | Pages: No page available

10.1161/jaha.124.036140 | PMID 39547991 Get It

Background White matter hyperintensities (WMH) and their progression are associated with risk of dementia and stroke, so are an important target for clinical trials. The cost of broad magnetic resonance imaging (MRI) screening to identify eligible individuals, however, limits the feasibility of designing clinical trials targeting WMH. A low‐cost retinal or clinical screening measure before MRI could reduce recruitment costs versus an MRI‐only screening design in a hypothetical clinical trial. Methods and Results Data from the Atherosclerosis Risk in Communities study with valid retinal and WMH measurements ( N =1311) were used. To identify a population at greater likelihood of significant WMH on MRI and thus reduce the number of screening MRIs required, we evaluated 3 theoretical prescreening measures: (1) retinal, (2) clinical, (3) combined clinical‐retinal. Given a target sample for clinical trials ( N =646), we calculated screening sample sizes based on the proportion within the population having an elevated score for each prescreening measure (separately) multiplied by the proportion of significant WMH among those with that prescreening feature. Recruitment costs were calculated using estimated retinal and MRI cost estimates. Compared with the estimated cost of MRI‐only screening (>$4.24 million, requiring MRI on 6526 participants), prescreening for a high clinical score resulted in total cost of $2.47 million, with an initial screening group of 52 778 participants, with MRI in 3801. A high clinical‐retinal score cutoff resulted in costs of $2.9 million while requiring 13 572 participants, with 3801 completing MRI. Conclusions A 2‐stage design with low‐cost prescreening measures is a promising approach, resulting in reduced theoretical recruitment costs compared with an MRI‐only design.
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, Alessandro , Petersen, René Horsleben , Stiles, Brendon M. , Wigle, Dennis A. , Collaborators, Platz, Joseph , Muesse, Jason , Grenda, Tyler R., Makey, Ian A. , Khandhar, Sandeep J. , Schipper, Paul H., Linsky, Paul L., Liptay, Michael J, Pechet, Taine, White, Abby , Wood, Douglas E. , Brandt, Whitney S. , Martin, Linda D., Patterson, Alec, Seder, Christopher W. , Lanita, Michael, Molena, Daniela , Lee, Jay M. , Healy, David , Decker, G. Anton , Sihoe, Alan , Zairi, Sarra , Dunning, Joel , Raveglia, Federico , Kleontas, Athanasios, Szántó, Zalán , Nosotti, Mario , Hudson, Jessica , Schneiter, Didier, Asadi, Nizar , Aranda, J.M. Botía, Congregado, Miguel , Backhus, Leah, Bertani, Alessandro , Nadal, Sergio Bolufer, Rosso, Lorenzo, Gattás, Gustavo, Augustin, Florian , Milton, Richard , Vannucci, Fernando , Waller, David , Gasparri, Mario, Reddy, Rishindra M. , Schreurs, W. H. , Saftić, Igor, Scarci, Marco, Toker, Seyfi Alper, Welcker, K , Furák, József, Durand, Marion, Hugen, Niek , Joseph, Lula Lukadi, Chiappetta, Marco , Pérez, María Rodríguez, Minasyan, Anna , Filose, Pier Luigi, Elkhayat, Hussein , Wei, Benjamin , Leone, Richard J., Chang, Albert S., Curcio, Carlo, Sparks, Preston, Hagen, Jeffrey A., Baste, Jean Marc , Taylor, Lauren , Xavier, D'journo, Hall, David Jeffrey, Hansen, Henrik Jessen, Leschber, Gunda, Koryllos, Aris , Gandhi, Shilpa , Batgirl, Hasan, Calvin, Ng Sze Hang, Sotiropoulos, Georgios C. , Furrer, Markus , Danjouma, Cheufou, Novoa, Nuria , Cassivi, Stephen D. , Veronesi, Giulia , Hamouri, Shadi , Štupnik, Tomaž , Hall, David J. , Antonoff, Mara B. , Collaborators, Louie, Brian E. , Daddi, Niccolò , Swisher, Stephen G. , Yendamuri, Sai S , Liptay, Michael J, Herrera, Luis, Martin, Linda, Patterson, Alec, Sandri, Alberto , Ruffini, Enrico , Maurizi, Giulio , Kleontas, Athanasios, Depypere, Lieven , Caruana, Edward Joseph , Mitchell, John , Gonfiotti, Alessandro , Pagès, P , Aranda, Jose, Billè, Andrea , Falcoz, Pierre‐Emmanuel , Rosso, Lorenzo , Terra, Ricardo Mingarini , Raemdonck, Dirk Van , Minervini, Fabrizio , Tosi, Davide , Solli, Piergiorgio , Scarci, Marco , Gooseman, Michael , Gossot, Dominique , Álvarez, Antonio , Toker, Seyfi Alper, Aramini, Beatrice , Guerrera, Francesco , Jiménez, Marcelo Fernando , Bölükbas, Servet , Thomas, P. A. , Luzzi, Luca , Aigner, Clemens , Minasyan, Anna, Kim, Young Tae , Pompili, Cecilia , Shargall, Yaron , Fiorelli, Alfonso , Curcio, Carlo, Bilfinger, Thomas V. , Engelhardt, Kathryn Elizabeth , Hall, David Jeffrey, Akopov, Andrey L. , Loos, Erik Robert de , Karamustafaoğlu, Yekta Altemur , Bertolaccini, Luca , Hendriks, Jeroen M. , Scanagatta, Paolo , Prisciandaro, Elena , Gómez-Hernández, María Teresa , Agrafiotis, Apostolos C. , Casiraghi, Monica , Danjouma, Cheufou Housmanou, Mariani, Alessandro Wasum , Antonio, David Gómez de , Bolca, Ciprian Nicolae , Cattaneo, Margherita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 15, 2024 | Volume: 66 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezae344 | PMID 39545513 Get It

Abstract 4147977: The association of Fontan fenestration patency on cardiopulmonary exercise performance in children and adults
Aviles, Laura Ortega, Opp, Derek N., Cetta, Frank , Allison, Thomas G. , Santos-Patarroyo, Sebastián

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147977 Get It

Background: Many children born with single ventricle physiology are palliated with Fontan operation, which may include a fenestration creation. This has been demonstrated to improve short-term outcomes after surgery. Reduced exercise capacity has been shown to be a predictor of prognosis in Fontan patients. Aim: We sought to compare cardiopulmonary exercise test (CPET) data between fenestrated and non-fenestrated Fontan patients. Methods: We conducted a retrospective cohort study of 185 patients referred for CPET from 2011 to 2024. Patients with complete CPET data were included. Type of Fontan, comorbidities, and echocardiogram data were ascertained electronically. Patients were divided into 2 different groups according to the fenestration patency. Fisher’s exact test or chi-square was used to compare categorical variables. T-test and Turkey-Kramer were used to compare continuous variables. Adjustment using General Lineal Models procedure were used to identify any confounder that could affect the results. P value <0.05 was considered significant. Results: 142 patients were classified in the non-fenestrated (NF) group, and 43 in the fenestrated group (FF). Baseline characteristics of both groups are shown in Table 1. From the evaluated CPET variables, the minute ventilation-carbon dioxide production (VE/VCO2) was higher in the FF (p=<0.001), and oxygen saturation at peak exercise (SatO2) was lower in this group (p= <0.001) (Figure 1). There was no significant difference between peak oxygen consumption (VO2) between groups. When adjusted by comorbidities only VE/VCO2 nadir, slope and peak SatO2 were statistically significant different between groups (Table 2). Conclusion: Ventilatory variables showed significant differences when fenestration was presented, secondary to V-Q mismatch from increased right to left shunt. Despite the theoretical advantage of increased cardiac output from Fontan fenestration, exercise performance was similar between both groups.
Abstract 4147904: Chronotropic Incompetence in Amyloid Cardiac Disease: A Marker of Severity?
Aviles, Laura Ortega, Grogan, Martha , Allison, Thomas G. , Santos-Patarroyo, Sebastián

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147904 Get It

Background: Cardiac amyloidosis is a rapidly progressing and severe condition leading to heart failure and reduced quality of life. Amyloid deposits impair both chronotropic and pumping functions of the heart. The Cardiopulmonary Exercise Test (CPET) is a vital tool in assessing the severity and progression of this disease. Aims: This study aims to investigate the differences in chronotropic function associated with the stages of heart failure in patients with cardiac amyloidosis and outcomes. Methods: A retrospective cohort study was conducted involving 194 patients diagnosed with cardiac amyloidosis who underwent at least one CPET from February 2010 to February 2024. Medical records were reviewed for data on the type of amyloidosis, comorbidities, and CPET results. The cohort was divided into two groups according to the Weber Classification: Weber Class A/B and Weber Class C/D. Patients who had CPET studies post-heart transplant were excluded. Statistical analyses, including Fisher’s exact test and chi-square test, were used. Cox regression model analysis, proportional hazards model for time to event. Adjustment for beta-blocker use was made to assess chronotropic incompetence. A p-value <0.05 was considered significant. Results: Among the 194 patients, 94 were classified as Weber A/B and 100 as Weber C/D. The average age at the time of the stress test was similar between the groups: 62.9 ± 11.7 years for Weber A/B and 62.3 ± 10.7 years for Weber C/D (p=0.087) Table 1 . Chronotropic function, evaluated through CPET, showed significant differences. Heart rate reserve was significantly lower in the Weber C-D group compared to the A-B group (p<0.001). The chronotropic index was also significantly lower in the Weber C-D group Figure 2. Chronotropic incompetence was observed in 43.9% of the Weber A and increased progressively, being significantly more prevalent in the Weber D group (100%) (p<0.001). Additionally, Chronotropic incompetence was strongly associated with the composite outcome of (hospitalization for heart failure and death) HR 1.932 (1.126 -3.313) p =0.0167 (Table 2). Conclusion: CPET assessment of chronotropic function correlates with VO2 parameter evaluated in Weber classification. Patients with higher Weber stages of heart failure in amyloidosis exhibited a higher prevalence of chronotropic incompetence, indicating it could serve as a marker of cardiac function.
Abstract 4147807: Peak Oxygen Uptake Changes as a Function of Lean Mass After Cardiac Rehabilitation
Elkhatib, Wiaam , Olson, Thomas P.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147807 Get It

Introduction: Peak oxygen uptake (VO 2 peak), standardized to total body mass (ml/kg/min) is a predictor of morbidity and mortality in cardiovascular disease patients. However, subsets of individuals undergoing exercise based cardiac rehabilitation (CR) show no improvement or reduction in VO 2 peak despite improvement in other functional measures. Hypothesis: Change in peak VO 2 post-CR, adjusted for lean mass rather than total mass better reflects peak VO 2 improvements. Aim : To assess the influence of CR on lean mass and the effect of lean mass compared to total body mass changes on peak VO 2 following CR. Methods: This observational cohort study included adults >18 years old who completed CR between 2015-2022 at Mayo Clinic, Rochester. All patients completed both dual energy X-ray absorptiometry (DXA) and cardiopulmonary exercise testing (CPET) for measurement of body composition (total mass and lean mass) and VO 2 peak pre- and post-CR. Improvement in VO 2 peak was defined as >% increase. Paired t-tests, one-way ANOVA, and descriptive statistics were performed. Results: Of 145 subjects, 81% were male and 63% Caucasian with a mean (SD) age of 62.8±12.6 years, BMI of 30.3±5.7, and 33.4±8.2 of 36 prescribed (92.8%) CR sessions completed. Pre-CR, patients demonstrated absolute VO 2 peak of 1,997.0±693.5 mL/min, relative of 22.1±6.2 mL/kg/min, and relative to lean mass of 35.2±9.6 mL/kg lean/min. After CR, patients demonstrated 1.2±3.1 kg reduction in total mass (p<0.05) and 0.4±1.7 kg increase in lean mass (p<0.05). Post-CR VO 2 peak increased by 17.1±117.0% absolute units (mL/min) (p<0.05), 9.0±16.1 % relative units (mL/kg/min) (p<0.05), and 15.9±111.9% units relative to lean mass (mL/kg lean/min) (p<0.05). Absolute and relative to lean mass units demonstrated greater improvements in VO 2 peak compared to relative units (p<0.05). Dependent on units, 70.3% of patients demonstrated an improvement in absolute VO 2 , 75.2% patients improved relative VO 2 , and 62.8% patients improved VO 2 relative to lean mass. Conclusions: These data demonstrate significant increases in lean mass and VO 2 following CR, with larger improvements reflected in units adjusted for lean mass compared to traditional relative units. In contrast, the largest proportion of patients showed positive improvements in VO 2 peak relative units with the smallest proportion relative to lean mass. These data suggest the reporting methodology for change in VO 2 following CR may impact overall findings.
Abstract 4146528: Pre-Heart Transplant Physical Rehabilitation in Patients on Impella Support Improves AMPAC Scores and Functional Status
Jonna, Sadhana , Raavi, Lekhya , Rodriguez, Allison Perez, Passi, Jatin Kumar, Khanijo, Aditya , Balasubramaniam, Prasanth, Mundhra, Gunjan, Hanson, Abby , Jena, Anek , Saleem, Faiz , Hannon, Rachel, Leoni, Juan , Lyle, Melissa , Thomas, Mathew , Sareyyüpoğlu, Başar , Sura, Lydia, Davis, Olivia , Birst, Jennifer, Worsowicz, Greg, Patel, Parag, Sanghavi, Devang , Huespe, Iván , Isha, Shahin , Jenkins, Anna , Leoni, Juan Carlos , Pham, Si M. , Franco, Pablo Moreno

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4146528 Get It

Introduction/Background: Patients with heart failure and those waiting for a heart transplant often experience a significant decrease in their ability to perform daily activities and exercise, leading to a lower quality of life. Although exercise-based cardiac rehabilitation (EBCR) is a possible treatment option, its effectiveness has not been well measured, resulting in limited adoption. Research Questions/Hypothesis: Could physical rehabilitation before receiving a heart transplant improve functional status and better outcomes? Goals/Aims: Our objective is to evaluate the effect of pre-transplant physical therapy on the standardized improvement of AM-PAC scores, measured from the earliest pre-transplant assessment to the most recent pre-transplant evaluation. Our second objective is to assess the impact of the latest Pre-Transplant AM-PAC Score on the number of hospital-free days following transplantation. Methods: We conducted a retrospective study on 91 heart transplant patients who received Impella support from January 2019 to April 2023, approved by the Mayo Clinic Institutional Review Board. We collected data on demographics, AMPAC scores, and outcomes at three time points. Continuous variables were compared using the T-test or Mann-Whitney test, and categorical variables using the Chi-square or Fisher's exact test. We used a linear regression model to investigate the relationship between rehabilitation duration and AMPAC scores. Quantile regression was preferred due to the non-normal distribution of the outcome, hospital-free days. Results: We conducted a linear regression analysis and found a statistically significant association between increased hours spent in PT and greater improvement. After one hour of physical therapy, there was an average increase of 1.07 (95% CI 0.1, 2; p=0.03) in AMPAC scoore. We also compared the change in the AMPAC score with hospital-free days, and it was statistically significant in quantile regression analysis, indicating an increase of 0.28 (95% CI 0.2, 0.55; P=0.03) points in the AMPAC Score, corresponding to an additional hospital-free day. Conclusion: Increased hours spent in physical therapy show a significant positive association with greater improvement in standardized AM-PAC Mobility scores and hospital-free days. These findings encourage increasing uptake and support of cardiac rehabilitation programs.
A Novel Machine Learning Model to Predict Revision ACL Reconstruction Failure in the MARS Cohort
Group, MARS, Vasavada, Vrinda, Devana, Sai K. , Hame, Sharon L. , Jazrawi, Laith M. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Amendola, Annunziato, Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Dunn, Warren R. , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hannafin, Jo A., Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., Wright, Rick W. , York, James J. , Group, MARS, Vasavada, Kinjal , Moran, Jay T. , Lee, Chang Hee , Sherman, Orrin H. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 14, 2024 | Volume: 12 | Issue: 11 | Pages: No page available

10.1177/23259671241291920 | PMID 39555321 Get It

Background: As machine learning becomes increasingly utilized in orthopaedic clinical research, the application of machine learning methodology to cohort data from the Multicenter ACL Revision Study (MARS) presents a valuable opportunity to translate data into patient-specific insights. Purpose: To apply novel machine learning methodology to MARS cohort data to determine a predictive model of revision anterior cruciate ligament reconstruction (rACLR) graft failure and features most predictive of failure. Study Design: Cohort study; Level of evidence, 3. Methods: The authors prospectively recruited patients undergoing rACLR from the MARS cohort and obtained preoperative radiographs, surgeon-reported intraoperative findings, and 2- and 6-year follow-up data on patient-reported outcomes, additional surgeries, and graft failure. Machine learning models including logistic regression (LR), XGBoost, gradient boosting (GB), random forest (RF), and a validated ensemble algorithm (AutoPrognosis) were built to predict graft failure by 6 years postoperatively. Validated performance metrics and feature importance measures were used to evaluate model performance. Results: The cohort included 960 patients who completed 6-year follow-up, with 5.7% (n = 55) experiencing graft failure. AutoPrognosis demonstrated the highest discriminative power (model area under the receiver operating characteristic curve: AutoPrognosis, 0.703; RF, 0.618; GB, 0.660; XGBoost, 0.680; LR, 0.592), with well-calibrated scores (model Brier score: AutoPrognosis, 0.053; RF, 0.054; GB, 0.057; XGBoost, 0.058; LR, 0.111). The most important features for AutoPrognosis model performance were prior compromised femoral and tibial tunnels (placement and size) and allograft graft type used in current rACLR. Conclusion: The present study demonstrated the ability of the novel AutoPrognosis machine learning model to best predict the risk of graft failure in patients undergoing rACLR at 6 years postoperatively with moderate predictive ability. Femoral and tibial tunnel size and position in prior ACLR and allograft use in current rACLR were all risk factors for rACLR failure in the context of the AutoPrognosis model. This study describes a unique model that can be externally validated with larger data sets and contribute toward the creation of a robust rACLR bedside risk calculator in future studies. Registration: NCT00625885 (ClinicalTrials.gov identifier).
Abstract 4145199: Prevalence and Prognostic Implications of Sleep Disordered Breathing in Hypertrophic Cardiomyopathy
Venkataraman, Shreyas , Deshmukh, Abhishek , Siontis, Konstantinos, Konecny, Thomas, Geske, Jeffrey B. , Geske, Jeffrey B , Karim, Shahid , Chahal, C. Anwar A. , Mansukhani, Meghna P. , Khanji, Mohammed Y , Petersen, Steffen E. , Somers, Virend K.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4145199 Get It

Background: Sleep disordered breathing (SDB) is frequently observed in patients with cardiovascular disease, and is associated with intermittent hypoxia, sympathetic activation, oxidative stress, and endothelial dysfunction, all of which may facilitate the development and progression of cardiovascular disease. Objectives: We sought to determine the prevalence, subtypes, and clinical implications of comorbid SDB in patients with hypertrophic cardiomyopathy (HCM). Methods: In this prospective observational study, patients with HCM without prior diagnosis of SDB were recruited to undergo inpatient polysomnography between May 1 st 2018 and October 31 st 2022. Electrocardiographic and echocardiographic parameters, cardiac biomarkers, and symptoms were comparatively assessed in patients with and without comorbid SDB. Patients were assessed for the development of major adverse cardiovascular events (MACE) during follow-up (median 29, range 3-57 months). Results Among 154 participants, 91 (59.1%) were diagnosed with SDB of whom 38 (41.8%) had mild, 22 (24.2%) moderate, 18 (19.8%) severe obstructive sleep apnea, and 13 (14.3%) had central sleep apnea. SDB was associated with greater left ventricular mass (median [IQR]) (128 [107, 161] vs. 109 [96, 134] g/m 2 , p =0.034) and E/e’ ratio (12.5 [10, 15] vs. 10.0 [8.3, 14.5], p =0.039). Patients with HCM over the age of 50 years, with body mass index ≥ 30kg/m 2 , who described their sleep as “poor” were at particularly high risk of having comorbid SDB, as were those who were diabetic, hypertensive, or described greater exertional limitation (NYHA Class ≥II 53% vs. 27%, p =0.005). Importantly, subjects with SDB had elevated baseline Troponin T levels (14 ng/L vs 11 ng/L, p =0.030), and further substantial overnight troponin increases following untreated apneic sleep (2.1ng/L vs 0.2ng/L, p =0.009). Finally, patients with comorbid SDB experienced a significantly higher proportion of incident adverse cardiovascular events (MACE hazard ratio 5.3, 95% CI, 1.6, 17.2, p =0.006) than those without SDB. Conclusions: We report a particularly high burden of previously undiagnosed SDB in patients with HCM, particularly in older, heavier, male patients. Undiagnosed SDB in HCM is not benign and is associated with symptom progression, comorbidity, and a poorer prognosis, particularly in the case of central sleep apnea. These important new findings provide rationale for heightened vigilance and routine screening for SDB in patients with HCM.